Anbio Biotechnology NNNN

NASDAQ NNNN
$4.08 +0.19 (+4.88%)
At close: Nov 9, 2026 · 4:00 PM EST

Anbio Biotechnology (NNNN) stock price is $4.08, up 4.88% on the day, as of Nov 9, 2026. It has a market cap of $175.12Mn and a P/E ratio of 24.76, and is classified in the Diagnostic Equipment industry (Healthcare sector).

Key Stats
Market Cap175.12 Mn
P/E24.76
FCF (Yr)-6.74 Mn
ROA (Yr)26.05
EV to EBIT82.45
Net Income (Yr)6.40 Mn
Enterprise Value128.35 Mn
Add ratio to table…

About

Anbio Biotechnology is a medical technology company focused on the development and supply of in vitro diagnostic products. The company designs assays that detect biomarkers related to infectious diseases cancer cardiovascular conditions inflammation drug abuse endocrine disorders renal disease pharmacogenomics and diabetes. It works with third party laboratories to create the assays and then contracts manufacturers to produce the final products for sale. Revenue comes from…

Read more ↓
Sector: Healthcare Sector rationale Anbio Biotechnology develops and sells in vitro diagnostic products, including antigen tests and PCR products, which fall under the Medical Devices and Diagnostic Equipment industries within the Healthcare sector. Its primary customers are hospitals, clinics, and laboratories, and its revenue is derived from the sale of these medical diagnostic kits and instruments. Industry: Diagnostic Equipment Diagnostic Equipment Primary Anbio Biotechnology designs and sells in vitro diagnostic kits and instruments, including real-time PCR and chemiluminescence immunoassay products. Its revenue is derived from the sale of these diagnostic machines and the associated assays to hospitals, clinics, and laboratories. Classified using BQ-MICS CIK: 0001982708

Geographical Breakdown of Revenue (2025)

History
Peer percentiles

How Anbio Biotechnology ranks

Ranked against the 247 companies in Medical Devices and Diagnostics58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/E 24.8xMedian 26.9x 88th
  • P/FCFNegative free cash flow −77.5xMedian 26.4x 56th
  • P/Operating cash flow —Median 21.3x No data —
  • P/S 60.4xMedian 2.88x 6th
  • P/B 17.3xMedian 2.30x 4th
  • P/Tangible book 17.3xMedian 2.97x 7th
  • EV/EBITDA —Median 17.5x No data —
  • EV/EBIT —Median 26.6x No data —
  • EV/Revenue —Median 3.14x No data —
  • EV/FCF —Median 29.7x No data —
  • EV/Operating cash flow —Median 21.1x No data —
  • PEG (3Y EPS CAGR) —Median 0.89 No data —
Peer group

Peer Comparison

Companies in the Diagnostic Equipment
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 267.71 Bn37.865.6541.37 Bn
2 ABT Abbott Laboratories 191.69 Bn40.783.9731.16 Bn
3 DHR Danaher Corp /De/ 166.18 Bn38.376.4926.48 Bn
4 ISRG Intuitive Surgical Inc 161.07 Bn54.4713.91-
5 MDT Medtronic plc 131.65 Bn25.173.5128.15 Bn
6 SYK Stryker Corp 125.25 Bn34.574.7614.93 Bn
7 BSX Boston Scientific Corp 63.85 Bn18.233.0311.95 Bn
8 NNNN Anbio Biotechnology 0.18 Bn24.7660.41-